Genome-wide association studies (GWAS) have established the cyclin-dependent kinase inhibitor (CDKN)2a locus, also called INK4a/ARF, as a hotspot influencing genetic risk for cardiovascular and metabolic diseases including T2D. This evidence concerns the gene CDKN2A and Other metabolic disease.